Armaron is pleased to announce that Brian Daniels, MD has been appointed to the Board of Directors of Armaron.
Prior to his joining, Brian spent two plus decades in clinical drug development in the industry; the last 10 years as the leader of Development and Medical Affairs at Bristol-Myers Squibb. He directed the development of numerous innovative medicines that have contributed to the improvement in health for patients across a range of serious diseases. These include: ORENCIA and NULOJIX in immunology/transplant, REYATAZ, DAKLINZA and BARACLUDE in virology, ELIQUIS in thrombosis/atrial fibrillation, ONGLYZA and FARXIGA in diabetes, ABILIFY in depression, MYOLEPT in rare diseases, SPRYCEL, OPDIVO, ERBITUX, YERVOY and IXEMPRA in oncology. Brian received a BS and MS from MIT and his MD from Washington University in St. Louis. He trained in internal medicine at New York Hospital and Rheumatology/Immunology at UCSF.